| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 沧州创融股权投资基金有限公司 | 0 | 39.21% | — | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO of 君圣泰医药-B (02511) achieved a 32.22x oversubscription, indicating moderate retail demand but falling short of market frenzy levels. With a hit rate of 44.15%, over half of applicants walked away empty-handed, and the final offer price data is missing, limiting pricing commentary. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Both A-tail and B-head applicants were allocated just 1 lot each, despite applying for 800 and 900 lots respectively—a mere 0.125% allocation, erasing the typical efficiency edge of B-head. This anomaly makes the B-head application cost-inefficient due to higher margin costs without any gain in shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
No demographic breakdown (Mainland/HK ratios, regional data) is available for this listing, possibly due to reporting gaps for pharmaceutical B-shares, limiting analysis of investor composition. Without this data, common trends like Guangdong dominance or mainland participation cannot be confirmed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Hightide-B (02511): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

